[CAS NO. 455264-30-9] Zaurategrastethylester
PRODUCTS SPECIFICATIONS [455264-30-9]
DESCRIPTION [455264-30-9]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 549.46 |
| Molecular Formula | C28H29BrN4O3 |
| SMILES | O=C(OCC)[C@H](CC1=CC=C(NC2=NC=CC3=C2C=NC=C3)C=C1)NC4=C(Br)C(C45CCCCC5)=O |
Summary
IC50 & Target
α4β1/α4β7 integrin [1]
In Vitro
Zaurategrast ethyl ester (CDP323), an ethyl ester prodrug of CT7758, shows some improvements in increasing mass transfer [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00726648 | UCB Pharma|Biogen |
Relapsing Multiple Sclerosis
|
July 2008 | Phase 1|Phase 2 |
| NCT00484536 | UCB Pharma|Biogen |
Multiple Sclerosis
|
May 2007 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 150 mg/mL ( 273.00 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.8200 mL | 9.0998 mL | 18.1997 mL |
| 5 mM | 0.3640 mL | 1.8200 mL | 3.6399 mL |
| 10 mM | 0.1820 mL | 0.9100 mL | 1.8200 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.55 mM); Clear solution
References
- [1] Chanteux H, et al. Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. Drug Metab Dispos. 2015 Sep;43(9):1381-91.
- [2] Davenport RJ, et al. Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases? Drug Discov Today. 2007 Jul;12(13-14):569-76.
